Corporate Presentation

Inflammation Our pre-clinical pipeline targets chronic inflammatory diseases with significant unmet medical needs Kv1.3 blocker (ZP9830) Targeting a broad set of chronic inflammatory diseases . Complement C3 inhibitor (ZP10068) ZEAL& ZEALAND PHARMA Partnered with Alexion for complement driven diseases 2000- IFN-g [pg/ml] 1500 1000- 500 0 -14 -12 -10 -8 Compound conc [log M] Concentration-dependent inhibition of pro- inflammatory cytokine release (including IFN-g, IL-2 and IL17A) from stimulated human whole blood1 . . In 2023, Zealand has completed activities to support advancing ZP10068 into clinical studies All subsequent regulatory, clinical, and development efforts will be led and conducted by Alexion USD 610 million potential development, regulatory and commercial milestones + high single to low double digits % royalties on net sales 1Data on file. Concentration-dependent effect on pro-inflammatory cytokine release from Thapsigargin stimulated whole blood. 44

View entire presentation